Selecta Biosciences to Participate at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Selecta Biosciences (NASDAQ: SELB) announced that its CEO, Carsten Brunn, Ph.D., will present a corporate update at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 1 at 9:30 a.m. ET and will be accessible via the Jefferies conference portal. Selecta's ImmTOR™ platform is designed to develop therapies that address unwanted immune responses, with programs targeting rare metabolic disorders and autoimmune diseases, along with ongoing collaborations in clinical trials.

WATERTOWN, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021.

The presentation on Tuesday, June 1 at 9:30 a.m. ET will be available through the Jefferies conference portal and an archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

FAQ

What is Selecta Biosciences' presentation schedule at the Jefferies Virtual Healthcare Conference?

Selecta Biosciences' CEO, Carsten Brunn, will present on June 1 at 9:30 a.m. ET.

Where can I access Selecta Biosciences' presentation from the Jefferies Virtual Healthcare Conference?

The presentation will be available through the Jefferies conference portal and later on Selecta's website.

What therapies is Selecta Biosciences currently developing?

Selecta is developing therapies using its ImmTOR™ platform to mitigate unwanted immune responses, focusing on rare metabolic disorders and autoimmune diseases.

When is Selecta Biosciences expected to enter clinical trials for its programs?

Selecta's first program addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021.

What is the stock symbol for Selecta Biosciences?

The stock symbol for Selecta Biosciences is SELB.